載入中
NASDAQHealthcareBiotechnology
最新資料
US$3.21
−US$0.11 · -3.31%
Alterity Therapeutics Limited, an Australian biopharmaceutical firm, focuses on the discovery and development of novel drug treatments for various neurological disorders, such as Alzheimer's, Huntington's, and Parkinson's diseases. Its prominent experimental therapy, ATH434, has completed Phase I clinical trials targeting Parkinson's disease. The company is also advancing PBT2, a compound that has successfully undergone Phase IIa clinical testing for Alzheimer's disease. Established in 1997, the entity was formerly known as Prana Biotechnology Limited before rebranding to Alterity Therapeutics Limited in April 2019, and its main operations are based in Melbourne, Australia.
一般交易時段
US$3.21
−US$0.11 · -3.31%
盤中時間採用ET。市場資料可能有所延遲。
Alterity Therapeutics Limited, an Australian biopharmaceutical firm, focuses on the discovery and development of novel drug treatments for various neurological disorders, such as Alzheimer's, Huntington's, and Parkinson's diseases. Its prominent experimental therapy, ATH434, has completed Phase I clinical trials targeting Parkinson's disease. The company is also advancing PBT2, a compound that has successfully undergone Phase IIa clinical testing for Alzheimer's disease. Established in 1997, the entity was formerly known as Prana Biotechnology Limited before rebranding to Alterity Therapeutics Limited in April 2019, and its main operations are based in Melbourne, Australia.
日內區間
目前US$3.21
52週區間
目前US$3.21
盤中時間採用ET。市場資料可能有所延遲。
Alterity Therapeutics Limited, an Australian biopharmaceutical firm, focuses on the discovery and development of novel drug treatments for various neurological disorders, such as Alzheimer's, Huntington's, and Parkinson's diseases. Its prominent experimental therapy, ATH434, has completed Phase I clinical trials targeting Parkinson's disease. The company is also advancing PBT2, a compound that has successfully undergone Phase IIa clinical testing for Alzheimer's disease. Established in 1997, the entity was formerly known as Prana Biotechnology Limited before rebranding to Alterity Therapeutics Limited in April 2019, and its main operations are based in Melbourne, Australia.
日內區間
目前US$3.21
52週區間
目前US$3.21
第三方分析師預期可能變動，並非 GoAI 建議。
AI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
